Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

BYOmass Inc
Profile last edited on: 8/18/20      CAGE: 7ZM19      UEI: N57BMT7GFJG6

Business Identifier: Therapeutics to modulate central control of metabolism associated with aging and age-related chronic illnesses.
Year Founded
2017
First Award
2019
Latest Award
2020
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

161 Pantry Road
Sudbury, MA 01776
   (860) 501-1575
   N/A
   N/A
Location: Single
Congr. District: 03
County: Middlesex

Public Profile

BYOMass Inc. is a preclinical metabolic disease biotech structured around development of therapeutics to modulate the central control of metabolism associated with aging and age-related chronic illnesses. In metabolic disease space, the focus / target is primarily on tissues - liver, muscle and pancreas. BYOmass principals indicate their focus will instead be focusing on how the brain controls metabolism - "more specifically ,how the hypothalamus and the brain stem perform…to help maintain food intake, body weight and blood pressure.

Extent of SBIR involvement

User Avatar
Phase I Awards
3
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$899,587
Phase II Dollars
$55,000
Total Awarded
$954,587

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2020 1 NIH $354,845
Project Title: Identification of First in Class Small Molecule GFRAL Blockers for the Prevention and Reversal of Cancer Anorexia-Cachexia
2019 1 NIH $299,871
Project Title: Identification of Bi-Specific Antibodies to Inhibit Gdf-15 and Activin a for Anorexia-Cachexia
2019 1 NIH $299,871
Project Title: Identification of Bi-Specific Antibodies to Inhibit GDF-15 and Activin a for Anorexia-Cachexia

Key People / Management

  Vivienne Margaret Jackson -- Founder and CEO

Company News

Mar 27 2019
Juvenescence Capitalizes BYOMass Inc. with up to $6.5 million